featured
Continuous Every-2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Continuous Every-2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis in a Randomized Phase III Trial (IXORA-P)
Br J Dermatol 2018 Jun 01;178(6)1315-1323, RG Langley, K Papp, M Gooderham, L Zhang, C Mallinckrodt, N Agada, A Blauvelt, P Foley, P PolzerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.